Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 02 May 2018 Planned End Date changed from 11 Feb 2019 to 1 Sep 2019.
- 02 May 2018 Planned primary completion date changed from 11 Feb 2019 to 1 Sep 2019.
- 03 Jan 2018 Trial designed has been published in 71st Annual Meeting of the American Epilepsy Society.